Focal segmental glomerulosclerosis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of focal segmental glomerulosclerosis (FSGS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of FSGS for each country, as well as annualized case counts projected to the national population.

The patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s FSGS forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of FSGS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following FSGS patient populations:

  • Diagnosed incident cases of FSGS.
  • Diagnosed prevalent cases of FSGS.
  • Diagnosed incident cases of end-stage FSGS.
  • Diagnosed prevalent cases of end-stage FSGS.

Note: Coverage may vary by country.